Influence of farnesyl transferase inhibitor treatment on epidermal growth factor receptor status

Nuclear Medicine and Biology

Volumn 31, Issue 6, 2004, Pages 679-689

  Cornelissen, Bart ^a   Thonissen, Thomas ^a   Kersemans, Veerle ^a   Van De Wiele, Christophe ^b   Lahorte, Christophe ^a   Dierckx, Rudi A ^b   Slegers, Guido ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cancer; Epidermal growth factor; Epidermal growth factor receptor; Farnesyl transferase inhibitor; R115777

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; EPIDERMAL GROWTH FACTOR RECEPTOR; IODINE 123; IODINE 125; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB; TRACER;

ANIMAL TISSUE; ARTICLE; CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DRUG ABSORPTION; DRUG RECEPTOR BINDING; DRUG TISSUE LEVEL; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTERNALIZATION; LINEAR SYSTEM; MALE; MOUSE; NONHUMAN; RADIOACTIVITY; RADIOIODINATION; RECEPTOR UPREGULATION;

ALKYL AND ARYL TRANSFERASES; ANIMALS; CELL LINE; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; FARNESYLTRANSTRANSFERASE; HUMANS; IODINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; QUINOLONES; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REGRESSION ANALYSIS; TISSUE DISTRIBUTION;

EID: 3042794165     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2004.03.004     Document Type: Article

References (27)

1. Brunner T.B., Hahn S.M., Gupta A.K., Muschel R.J., McKenna W.G., Bernhard E.J. Farnesyltransferase inhibitors An overview of the results of preclinical and clinical investigations. Cancer Res. 63:2003;5656-5668
2. Favoni R.E., De Cupis A. The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach. Pharmacol Rev. 52:(2):2000;179-206
3. Wells A. EGF receptor. Int J Biochem Cell Biol. 31:(6):1999;637-643
4. Hackel P.O., Zwick E., Prenzel N., Ullrich A. Epidermal growth factor receptors critical mediators of multiple receptor pathways. Curr Opin Cell Biol. 1:1999;184-189
5. Gibbs J.B. Anticancer drugs targets growth factors and growth factor signalling. J Clin. Invest. 105:2002;9-13
6. Lamy J.P. HER-2 and trastuzumab A novel biological and therapy paradigm for breast cancer. Méd Nucl. 26:2002;46-50
7. End D.W., Smets G., Todd A.V., Applegate T.L., Fuery C.J., Angibaud P., Venet M., Sanz G., Poignet H., Skratz S., Wouters W., Bowden C. Characterisation of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 6:2001;131-137
8. Karp J.E., Lancet J., Kaufmann S., End D.W., Wright J.J., Bol K., Horak I., Tidwell M.L., Liesveld J., Kottke T.J., Ange D., Buddharaju L., Gojo I., Highsmith W.E., Belly R.T., Hohl R.J., Rybak M.E., Thibault A., Rosenblatt J. Clinical and biological activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 97:2001;3361-3369
9. Adjej A., Mauer A., Bruzek L., Marks R.S., Hillman S., Geyer S., Hanson L.J., Wright J.J., Erlichman C., Kaufman S.H., Vokes E.E. Phase II tudy of the farnesyl transferase inhibitor R115777 in patients with advanced nonsmall-cell lung cancer. J Clin Oncol. 21:2003;1760-1766
10. Adjei A., Erlichman C., Davis J., Cutler D.L., Sloan J.A., Marks R.S., Hanson L.J., Svingen P.A., Atherton P., Bishop W.R., Kirschmeier P., Kaufmann S.H. A phase I trial of the farnesyl transferase inhibitor SCH66336. Evid Biol Clin Activity Cancer Res. 60:2000;1871-1877
11. Fraker P.J., Speck J.C. Protein and cell membrane iodination with a sparingly soluble chloramine. Biochem Biophys Res Commun. 80:1978;849-856
12. Bylund D.B., Yamamura H.I. Methods for receptor binding. Methods in neurotransmitter receptor analysis. 1990;Raven Press, New York, NY. 1-35
13. Cairnie A.B., Leach K.E. Quantitative studies of cytological damage in mouse testis produced by exposure to heat. Can J Genet Cytol. 22:(1):1980;93-102
14. Olsson P., Collins V.P., Liu L., Gedda L., Liljegren A., Carlsson J. Internalisation and retention of EGF-dextran associated radioactivity in transfected Chinese hamster ovary cells expressing the human EGF-receptor. Int J Oncol. 20:2002;1057-1063
15. Ercan M.T., Senekowitsch R. 111In or 125I labeled epidermal growth factor for the in vivo loacalization of EGF receptors in vivo stability. J Islamic Acad Sci. 4:(2):1991;123-126
16. Neves M., et al. Synthesis, characterization and biodistribution of bisphosphonates Sm-153 complexes correlation with molecular modelling interaction studies. Nucl Med Biol. 29:(3):2002;329-338
17. 123I] iodo-PK11195 a possible single photon emission tomography tracer for visualizing inflammation. Eur J Nucl Med. 26:(3):1999;194-200
18. 123I-labelled Annexin V in mice a possible SPET-ligand for visualization of apoptotic cells. Nucl Med Commun. 20:(10):1999;948-949
19. Cornelissen B, Jans L, Kersemans V, Oltenfreiter R, Thonissen T, Achten E, Slegers G. Tumor volumetry methods in mice compared with 1 T MRI volumetry. MRI Biomed. submitted
20. Kienhuis C.B., Heuvel J.J., Ross H.A., Foekens J.A., Benraad T.J. High-performance liquid chromatography of 125I-labelled mouse epidermal growth factor radioiodinated by six different methods. Clin Chem. 38:1992;681-686
21. Vargas G.A., Fantino E., George-Nascimento G., Gargus J.J., Haigler H.T. Reduced epidermal growth factor receptor expression in hypohidrotic ectodermal dysplasia and tabby mice. J Clin Invest. 97:1996;2426-2432
22. Caraglia M, Tagliaferri P, Correale P, Genua GA, Pinto, Del Vecchio S, Esposito G, Bianco AR. Epidermal growth factor and transferrin receptor upregulation is induced by arabinoside cytosine on human tumor cells. Cancer Detect Prev 1993:17(2):337
23. Rao CV, Carman FR, Chegini N, Schultz GS. Binding sites for epidermal growth factor in human fetal membranes. J Clin Endocrin Metab 58:1034-42
24. Suzuki N., Keith Del Villar K., Tamanoi F. Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents. Proc. Natl. Acad. Sci. USA. 95:(18):1998;10499- 10504
25. Cornelissen B., Allaert A., Slegers G. Radioiodinated IGF-I as a possible biomarker for monitoring the effect of the farnesyl transferase inhibitor R115777. Eur J Nucl Med Molec Imag. 30:(S2):2003;S191
26. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 19:2000;6550-6565
27. Chailler P, Ménard D. Ontogeny of EGF receptors in the human gut. Front Biosci 1999;4:D87-101